Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial
Mitsue Saito, Kenjiro Aogi, Ikuo Sekine et al. · The Lancet Oncology · 2009
Cited by 425 works. doi:10.1016/s1470-2045(08)70313-9
Authors
- Mitsue Saito
- Kenjiro Aogi
- Ikuo Sekine
- Hirohisa Yoshizawa
- Yasuhiro Yanagita
- Hiroshi Sakai
- Kenichi Inoue
- Chiyoe Kitagawa
- Takashi Ogura
- Shoichi Mitsuhashi
References
- American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
- Proposal for classifying the acute emetogenicity of cancer chemotherapy.
- Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
- Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics
- Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.
- Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy
- Dexamethasone, Granisetron, or Both for the Prevention of Nausea and Vomiting during Chemotherapy for Cancer
- Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference
- Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonist
- Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy